Bank of New York Mellon Corp bought a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 68,145 shares of the company's stock, valued at approximately $5,848,000. Bank of New York Mellon Corp owned 0.23% of Establishment Labs at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. KBC Group NV purchased a new position in Establishment Labs in the 1st quarter valued at about $28,000. Quarry LP purchased a new position in shares of Establishment Labs in the 3rd quarter worth about $34,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs in the 4th quarter valued at about $47,000. Osaic Holdings Inc. lifted its stake in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock valued at $85,000 after purchasing an additional 1,800 shares in the last quarter. Finally, State of Wyoming purchased a new stake in shares of Establishment Labs during the 2nd quarter worth about $87,000. Institutional investors and hedge funds own 72.91% of the company's stock.
Analysts Set New Price Targets
Several equities analysts recently commented on ESTA shares. Needham & Company LLC boosted their price target on Establishment Labs from $86.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Mizuho boosted their price objective on shares of Establishment Labs from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their target price on shares of Establishment Labs from $84.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. TD Cowen raised their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Finally, Citigroup raised shares of Establishment Labs from a "neutral" rating to a "buy" rating and set a $92.00 price objective on the stock in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $100.25.
Get Our Latest Analysis on ESTA
Establishment Labs Stock Up 2.8%
Shares of ESTA opened at $74.29 on Friday. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The company has a 50-day simple moving average of $83.45 and a 200-day simple moving average of $74.89. Establishment Labs Holdings Inc. has a 52 week low of $36.53 and a 52 week high of $97.59. The firm has a market capitalization of $2.21 billion, a P/E ratio of -56.71 and a beta of 1.05.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The business had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The business's revenue for the quarter was up 31.7% on a year-over-year basis. During the same period last year, the company earned ($0.57) EPS. On average, equities research analysts expect that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.
Establishment Labs Company Profile
(
Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Featured Articles
Want to see what other hedge funds are holding ESTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
